Douglas A Stewart

Douglas A Stewart

UNVERIFIED PROFILE

Are you Douglas A Stewart?   Register this Author

Register author
Douglas A Stewart

Douglas A Stewart

Publications by authors named "Douglas A Stewart"

Are you Douglas A Stewart?   Register this Author

56Publications

1559Reads

39Profile Views

Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.

J Natl Compr Canc Netw 2019 08;17(8):957-967

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.7286DOI Listing
August 2019

The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 12 29;18(12):829-835. Epub 2018 Aug 29.

Departments of Oncology and Medicine, University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.08.015DOI Listing
December 2018

Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation.

J Oncol Pharm Pract 2018 Jul 30;24(5):323-331. Epub 2017 Mar 30.

4 Department of Oncology, University of Calgary and Tom Baker Cancer Centre, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155217702214DOI Listing
July 2018

Targeting non-Hodgkin lymphoma with blinatumomab.

Expert Opin Biol Ther 2017 08 1;17(8):1013-1017. Epub 2017 Jun 1.

b Departments of Medicine and Oncology , University of Calgary and Tom Baker Cancer Centre , Calgary , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1334053DOI Listing
August 2017

Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.

Hematol Oncol 2017 Mar 10;35(1):79-86. Epub 2015 Sep 10.

Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, University of Calgary/Calgary Laboratory Services (CLS), Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2251DOI Listing
March 2017

Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.

Leuk Lymphoma 2016 27;57(1):28-33. Epub 2015 Mar 27.

a Department of Oncology and Medicine , University of Calgary, Tom Baker Cancer Centre , Calgary , AB , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1026901DOI Listing
October 2016

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2016 09 28;22(9):1654-1663. Epub 2016 May 28.

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Bone Marrow and Blood Cell Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.05.020DOI Listing
September 2016

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis.

Biol Blood Marrow Transplant 2016 May 16;22(5):941-8. Epub 2016 Jan 16.

Departments of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.01.015DOI Listing
May 2016

CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series.

J Clin Pathol 2015 Oct 29;68(10):844-8. Epub 2015 Jun 29.

Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, University of Calgary/Calgary Laboratory Services (CLS), Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2015-202955DOI Listing
October 2015

Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective.

Ther Adv Hematol 2015 Aug;6(4):161-70

Departments of Medicine and Oncology, University of Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620715586528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530370PMC
August 2015

Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis.

Leuk Lymphoma 2015 Jun 3;56(6):1756-62. Epub 2014 Nov 3.

Department of Oncology and Medicine, University of Calgary, Tom Baker Cancer Centre , Calgary, AB , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.971409DOI Listing
June 2015

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

J Clin Oncol 2015 Jun 20;33(17):1936-42. Epub 2015 Apr 20.

Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.8138
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.8138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176PMC
June 2015

Obinutuzumab for B-cell malignancies.

Expert Opin Biol Ther 2014 Aug 23;14(8):1197-205. Epub 2014 May 23.

University of Calgary, Tom Baker Cancer Centre, Division of Hematology and Hematological Malignancies , 603 South Tower, Foothills Medical Centre, 1403-29th St NW, Calgary, Alberta, T2N 2T9 , Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2014.922535DOI Listing
August 2014

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

N Engl J Med 2013 Oct;369(18):1681-90

From Loyola University Medical Center, Maywood, IL (P.J.S., K.P.B.); Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle (J.M.U., M.L.); Cleveland Clinic, Cleveland (J.R.C., R.R.T.); University of Rochester, Rochester, NY (L.S.C., J.W.F., R.I.F.); Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS (S.C.), University of Calgary-Tom Baker Cancer Centre, Calgary, AB (D.A.S.), and Margaret and Charles Juravinski Cancer Centre, Hamilton, ON (D.M.) - all in Canada; University of North Carolina at Chapel Hill, Chapel Hill (T.C.S.); Ohio State University Medical Center, Columbus (P.P.); Northwestern University, Chicago (J.N.W.); University of Wisconsin, Madison (B.S.K.); University of Arizona, Tucson (T.P.M., L.M.R.); Louisiana State University Health Sciences Center, Shreveport (G.M.M.); City of Hope Medical Center, Duarte, CA (S.J.F.); and Fox Chase Cancer Center-Temple Health, Temple University School of Medicine, Philadelphia (R.I.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1301077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418PMC
October 2013

Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.

Leuk Lymphoma 2012 May 6;53(5):862-7. Epub 2011 Dec 6.

Department of Oncology and Medicine, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.633250DOI Listing
May 2012

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

Blood 2012 May 20;119(22):5118-25. Epub 2012 Mar 20.

British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-02-408773DOI Listing
May 2012

Obinutuzumab for the treatment of lymphoproliferative disorders.

Expert Opin Biol Ther 2012 Mar 28;12(3):343-51. Epub 2012 Jan 28.

Tom Baker Cancer Centre & University of Calgary, 1331-29th St NW, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2012.657622DOI Listing
March 2012

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

Biol Blood Marrow Transplant 2012 Feb 27;18(2):295-301. Epub 2011 Jul 27.

Alberta Blood and Marrow Transplant Program, Foothills Hospital, and Tom Baker Cancer Centre, 1331-29th Street N.W., Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2011.07.015DOI Listing
February 2012

Primary colorectal lymphoma-clinical outcomes in a population-based series.

J Gastrointest Surg 2011 Oct 7;15(10):1851-7. Epub 2011 Jun 7.

Department of Surgery, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-011-1572-0DOI Listing
October 2011

pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.

Leuk Lymphoma 2009 Aug;50(8):1276-82

Department of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190903015628DOI Listing
August 2009

The role of surgical intervention in the management of duodenal lymphoma.

J Surg Oncol 2009 Jun;99(7):428-32

Department of Surgery, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta T2N 4N2, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jso.21269
Publisher Site
http://dx.doi.org/10.1002/jso.21269DOI Listing
June 2009

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Biol Blood Marrow Transplant 2009 Jan;15(1):39-46

Department of Oncology and Medicine, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S108387910800452
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2008.10.018DOI Listing
January 2009

Association between exercise and quality of life in multiple myeloma cancer survivors.

Support Care Cancer 2004 Nov;12(11):780-8

Faculty of Physical Education, University of Alberta, E-424 Van Vliet Centre, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-004-0668-4DOI Listing
November 2004

Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation.

Leuk Lymphoma 2002 Dec;43(12):2421-3

Department of Medicine, Division of Hematology and Hematological Malignancies, University of Calgary, 3330 Hospital Dr. N.W. Calgary, Alta., Canada T2N 4N1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1042819021000040170DOI Listing
December 2002